Strategy
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Unlock global pharma market insights. NovaPharmaNews delivers strategic intelligence for investors, BD, and analysts to drive pharmaceutical growth.
Showing 1–12 of 32 articles
Quick answer
NovaPharmaNews Strategy hub for FDA covers 32 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win
Puma Biotechnology Inducement Awards: Strategic Talent Moves Under Nasdaq Rule 5635(c)(4)
Facet Life Sciences Appoints Frank Closurdo as VP, Commercial Services
Opinion: I led the CDC response to the 2014 Ebola epidemic. The new outbreak needs massive
Amish Health Beliefs: Vaccines, Costs, and Pharma Strategy Insights
Senior NIH official pushes MAHA strategy to skeptical ADA audience
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
OHRP Underfunding Risks Human Subject Protection in 2026
STAT+: RFK Jr.’s second year: Vacancies, not vaccines
HHS Confirms Americans with High-Risk Ebola Exposures Will Have Access to Experimental Therapy MBP-134
AI Titans Push Congress for DNA Safeguards: Implications for Biotech Strategy
Pharma Pulse: 340B Uncertainty, Drug Shortages, and Wegovy's Global Debut
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.